CARsgen Therapeutics Reports 2025 Interim Results and Regulatory Progress
CARsgen Therapeutics Holdings Limited (HKG: 2171) has announced its 2025 Interim Results, highlighting significant progress...
Superluminal Collaborates With Eli Lilly on Small Molecule Therapeutics for Cardiometabolic Diseases
Superluminal Medicines announced on August 14, 2025, a collaboration with Eli Lilly (NYSE: LLY) to...
Sanofi’s Rilzabrutinib Granted Orphan Drug Designation for IgG4-Related Disease by EMA
French pharmaceutical major Sanofi (NASDAQ: SNY) announced that it has received another orphan drug designation...
China’s NHSA Releases Interim Measures for Medical Case-Based Payment Management
The National Healthcare Security Administration (NHSA) issued the “Interim Measures for Medical Security Case-Based Payment...
Pfizer’s Emblaveo Prescribed in Shanghai Hospitals for First Time Nationwide
US giant Pfizer Inc. (NYSE: PFE) announced that its Emblaveo (aztreonam and avibactam) has been...
Insilico Medicine’s ISM8969 Nears Clinical Evaluation for Parkinson’s Disease
Insilico Medicine, a Chinese generative AI-driven biotech company, announced the completion of IND-enabling studies for...
SineuGene’s First-in-Class ALS Gene Therapy SNUG01 Gets NMPA Clinical Trial Clearance
Beijing-based SineuGene Therapeutics, a developer of gene therapies for brain disorders based in Beijing, announced that...
Fosun Pharma Issues China’s First Private Pharma Innovation Bond to Accelerate R&D
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has successfully issued the nation’s first...
Eli Lilly Hikes Mounjaro Price in UK by 170% for Private-Pay Patients
US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) announced on August 14, 2025, that...
Qihan Biotech’s QT-019B Gains FDA IND Approval for Autoimmune Diseases
Hangzhou Qihan Biotech Co., Ltd. announced that its self-developed universal dual-target CAR-T cell product, QT-019B,...
Novartis’ Ianalumab Shows Positive Results in Phase 3 Trials for ITP and Sjögren’s Disease
Swiss pharmaceutical giant Novartis (NYSE: NVS) announced positive top-line results from the Phase 3 VAYHIT2...
Everest Medicines’ Velsipity NDA Accepted for Review in Taiwan
China-based Everest Medicines (HKG: 1952) announced that the New Drug Application (NDA) for its Velsipity...
Hualan Biological Gains NMPA Approval for Hib Vaccine Clinical Trials
Hualan Biological Engineering Inc., (SHE: 002007) announced that its freeze-dried Haemophilus influenzae type b (Hib)...
RemeGen Announces Positive Phase III Results for Telitacicept in Primary Sjögren’s Syndrome
China-based RemeGen Co., Ltd. (SHA: 688331, HKG: 9995), a China-based pharmaceutical firm, announced on August...
China Issues Guidelines for Medical Advertisement Identification, Clarifies Scenarios and Regulations
The State Administration for Market Regulation (SAMR), in collaboration with the National Health Commission (NHC)...
MSD Officially Launches Zerbaxa in China to Tackle Drug-Resistant Infections
US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) announced on August 13, 2025, the...
Jiangsu Hengrui Establishes New Biopharmaceutical Unit to Strengthen Anesthesia and ICU Presence
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced on August 14, 2025,...
Jiangsu Hengrui’s Combo Therapy Approved for Clinical Trials by NMPA
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced on August 13, 2025,...
Henlius Biotech’s HLX04-O Accepted by NMPA for Wet AMD Treatment
Shanghai Henlius Biotech Inc. (HKG: 2696) announced on August 13, 2025, that the marketing authorization...
TYK Medicines’ Asandeutertinib Shows Promising Results in Phase II Trial for EGFR-Mutated NSCLC
China-based TYK Medicines, Inc. (HKG: 2410) announced on August 14, 2025, that the results of...